SS
AARD

Sunbelt Securities’s Aardvark Therapeutics AARD Stock Holding History

Sunbelt Securities’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15 Buy
+4
New +$41 ﹤0.01% 2900

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Sunbelt Securities's AARD Position: Q1 2026 in Review

Sunbelt Securities opened a new position in Aardvark Therapeutics (AARD) in Q1 2026: 4 shares worth $15. The stake represents ﹤0.01% of the portfolio and ranks #2900 among its holdings.

79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • Sunbelt Securities held 4 shares of Aardvark Therapeutics worth $15 as of Q1 2026.
  • Aardvark Therapeutics was a new Sunbelt Securities position in Q1 2026.
  • Aardvark Therapeutics made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2900 holding.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.